Tucotuzumab celmoleukin

{{Short description|Monoclonal antibody drug}}

{{Drugbox

| verifiedrevid = 450332018

| image =

| type = mab

| mab_type = mab

| source = zu/o

| target = EpCAM

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 339986-90-2

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4ON7FF680U

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09027

| ChemSpiderID = none

| C=7812 | H=12124 | N=2044 | O=2408 | S=60

}}

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[http://www.ama-assn.org/ama1/pub/upload/mm/365/t_celmoleukin.pdf Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin], American Medical Association.{{ClinicalTrialsGov|NCT00016237}}{{cite web | url = http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=456358 | work = National Cancer Institute | title = Definition of tucotuzumab celmoleukin }}

This drug was developed by EMD Pharmaceuticals.